Citigroup
BIAF icon

Citigroup’s bioAffinity Technologies BIAF Stock Holding History

Citigroup’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57
Closed -$218 – 5743
2026
Q1 		$218 Sell
57
-7,684
-99% -$12.4K ﹤0.01% 5573
2025
Q4 		$9.13K Buy
7,741
+7,666
+10,221% +$15.3K ﹤0.01% 5091
2025
Q3 		$222 Buy
75
+26
+53% +$207 ﹤0.01% 5758
2025
Q2 		$424 Buy
+49
New +$560 ﹤0.01% 5451

Other funds holding BIAF

JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup's BIAF Position: Q2 2026 in Review

Citigroup sold out of bioAffinity Technologies (BIAF) in Q2 2026, closing a stake of 57 shares — an estimated $218 sold.

Citigroup first reported a position in BIAF in Q2 2025 and held it in 4 quarters. The position peaked at $9.13K in Q4 2025. 14 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

  • Citigroup reported no remaining bioAffinity Technologies position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 57 bioAffinity Technologies shares in Q2 2026, an estimated $218.
  • Citigroup first reported a position in bioAffinity Technologies in Q2 2025 and held it in 4 quarters.
  • Citigroup's bioAffinity Technologies position peaked at $9.13K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.